Abstract 188P
Background
A thorough investigation of the tumor cells and immune microenvironment within the lead-edge area is essential for understanding the mechanisms behind the progression of ICC and devising a targeted therapy in the hope of providing clinical benefits for patients.
Methods
Here, we conducted an analysis based on single-cell RNA sequencing (scRNA-seq) and spatial transcriptome (ST) on samples from the tumor core, paired non-tumorous tissue, and the leading-edge area obtained from 9 ICC patients to delineate the properties of cancer cells, immune microenvironment, and the intricate intercellular interactions within. The analysis results were further validated using H&E staining, multiple immunofluorescence staining (IHC), and a large transcriptome dataset.
Results
Tumor cells at the leading-edge area exhibit a heightened capacity for proliferation compared to those in the tumor core, often found in close proximity to the stroma, including endothelial cells and POSTN+ FAP+ fibroblasts. Within this region, CD8+ T cells are characterized by a naive phenotype, displaying low levels of cytotoxicity and exhaustion, a condition that may be linked to the impaired antigen-presenting capabilities of antigen-presenting cells (APCs). MAIT cells, which are the predominant CD8+ T cell subset infiltrating the leading-edge area of ICC, have been observed to recruit SPP1+ macrophages and are co-localized with POSTN+ cancer-associated fibroblasts (CAFs) in the stromal compartment. The presence of SPP1+ macrophages could potentially foster tumor progression through the activation of CD44 in tumor cells, as well as by their proangiogenic effects.
Conclusions
Utilizing scRNA-seq and spatial transcriptome technologies, our research delineates the distinct characteristics of ICC tumor cells within the leading-edge area, revealing how they interact with and influence the surrounding stroma to sculpt the immune microenvironment. These orchestrated interactions within the tumor milieu offer valuable insights and pinpoint potential therapeutic targets for intervention.
Legal entity responsible for the study
Peking University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
137P - Hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab for unresectable hepatocellular carcinoma: A single-arm, phase II study
Presenter: Jianbing Wu
Session: Poster Display session
138P - Interim results of neoadjuvant TACE plus lenvatinib and tislelizumab in resectable HCC at CNLC stages IB and IIA with high-risk of recurrence: A prospective, single-arm, phase II trial
Presenter: Yuhua Zhang
Session: Poster Display session
139P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display session
140P - Tislelizumab combined with lenvatinib and transarterial chemoembolization(TACE) neoadjuvant treatment in resectable CNLC IIa-IIb hepatocellular carcinoma: A prospective, single-arm, phase II study
Presenter: Zhibo Zhang
Session: Poster Display session
141P - Efficacy and safety of tislelizumab(T) combined with gemcitabine and cisplatin(GC) for patients with localized muscle-invasive bladder cancer(MIBC) after radical local surgery: A prospective, phase II study
Presenter: Ming Cao
Session: Poster Display session
Resources:
Abstract
143P - Strength of patient (pt) preference for atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) for the treatment of NSCLC: exploratory analyses from the IMscin002 study
Presenter: Margarita Majem Tarruella
Session: Poster Display session
144P - First-line cemiplimab monotherapy for advanced non-small cell lung cancer (NSCLC) of squamous histology: Subgroup analysis with 5-year results from EMPOWER-Lung 1
Presenter: Tamta Makharadze
Session: Poster Display session